Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 15:12:474.
doi: 10.1186/1471-2407-12-474.

Adherence evaluation of endocrine treatment in breast cancer: methodological aspects

Anne S Oberguggenberger  1 , Monika Sztankay, Beate Beer, Birthe Schubert, Verena Meraner, Herbert Oberacher, Georg Kemmler, Johannes Giesinger, Eva Gamper, Barbara Sperner-Unterweger, Christian Marth, Bernhard Holzner, Michael Hubalek
Affiliations

Adherence evaluation of endocrine treatment in breast cancer: methodological aspects

Anne S Oberguggenberger et al. BMC Cancer. .

Abstract

Background: Current studies on adherence to endocrine therapy in breast cancer patients suffer from methodological limitations due to a lack of well-validated methods for assessing adherence. There is no gold standard for measuring adherence. The aim of our study was to compare four different approaches for evaluating adherence to anastrozole therapy for breast cancer with regard to concordance between methods.

Methods: Outpatients with early breast cancer treated with anastrozole completed the multi-method assessment of adherence. We implemented a self-report scale (the Simplified Medication Adherence Questionnaire), physician- ratings, refill records and determination of anastrozole serum concentration.

Results: Comparison of the four approaches using Spearman rank correlation revealed poor concordance across all methods reflecting weak correlations of 0.2-0.4. Considering this data incomparability across methods, we still observed high adherence rates of 78%-98% across measures.

Conclusion: Our findings contribute to the growing body of knowledge on the impact that methodological aspects exert on the results of adherence measurement in breast cancer patients receiving endocrine treatment. Our findings suggest that the development and validation of instruments specific to patients receiving endocrine agents is imperative in order to arrive at a more accurate assessment and to subsequently obtain more precise estimates of adherence rates in this patient population.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of anastrazole serum concentrations (presented in ng/ml).
See this image and copyright information in PMC

References

    1. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF. investigators AL. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–1141. doi: 10.1016/S1470-2045(10)70257-6. - DOI - PubMed
    1. Urquhart J. In: Compliance in Healthcare and Research. edn. Ockene LBI, editor. Futura Publishing Company, New York; 2001. Biological measures; pp. 105–117.
    1. Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993;11(6):1189–1197. - PubMed
    1. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology. 2006;71(1–2):1–9. - PubMed
    1. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–537. doi: 10.1007/s10549-010-1132-4. - DOI - PMC - PubMed

Publication types

MeSH terms